BRAF and neoplasm: It was also shown that melanoma tumor cell lines upregulate melanoma differentiation antigens on stimulation with a MEK inhibitor in vitro regardless of BRAF mutation status.64 In light of these observations, adding a MEK inhibitor to the BRAFi treatment or using a MEK inhibitor alone in BRAF wildtype patients might be considered in future TIL-based clinical trials.